Evogene (EVGN) Tops Q2 EPS by 15c

Evogene (NASDAQ: EVGN) reported Q2 EPS of ($0.13), $0.15 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $325 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• RBC Capital Starts Shake Shack (SHAK) at Outperform
• JPMorgan Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
• Barclays Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Equalweight